ArticleFrontiers in oncology2025
Proton beam radiation therapy vs. photon radiation therapy and the overall survival of adult and pediatric patients diagnosed with sarcoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Head and Neck Rhabdomyosarcoma in Children: An Otolaryngological Perspective on Diagnostic and Therapeutic Approaches.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of proton beam radiation therapy (PBT) has increased in patients diagnosed with sarcoma. However, there is a lack of information about its survival benefit in these patients. Objective: We want to investigate the association of PBT with the overall survival (OS) of sarcoma patients. Methods: We used the National Cancer Database and assessed the OS using multivariable Cox regression analysis adjusted for age, sex, race, education, income, insurance status, histology, comorbidity score, radiation therapy dose, chemotherapy, surgery, and year of diagnosis. Results: Among the 117,694 patients, 3,573 (3%) received PBT. Patients receiving PBT had longer OS than those receiving photon radiation therapy (PRT) (HR: 0.73, CI: 0.68 -0.79). PBT was also associated with improved OS compared to PRT in chordoma (HR: 0.57, CI: 0.44-0.74), rhabdomyosarcoma (HR: 0.58, 95% CI: 0.47- 0.72), or chondrosarcoma (HR: 0.35, CI: 0.24-0.51) patients. Among patients who received surgery, PBT was associated with improved OS compared to PRT in chordoma (HR: 0.37, CI: 0.22-0.60), chondrosarcoma (HR: 0.52, CI: 0.28-0.97), or osteosarcoma (HR: 0.32, CI: 0.12-0.89) patients. Among patients with no surgery, PBT was associated with improved OS compared to PRT in chordoma (HR: 0.57, CI: 0.44-0.74), rhabdomyosarcoma (HR:0.56, CI: 0.44-0.70), chondrosarcoma (HR:0.24, CI: 0.15-0.37), osteosarcoma (HR: 0.51, CI: 0.30- 0.87), or other histology type (HR:0.76, CI: 0.66-0.86) patients. Conclusion: The use of PBT was associated with improved OS compared to photon RT in sarcoma patients. PBT was associated with improved OS in patients diagnosed with chordoma, rhabdomyosarcoma, or chondrosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.